Seminars in Oncology
Volume 33 , Pages 3-7 , December 2006

Clinical Efficacy Supporting the Role of Intraperitoneal Drug Delivery in the Primary Chemotherapeutic Management of Small-Volume Residual Advanced Ovarian Cancer

  • Maurie Markman

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Maurie Markman, MD, Gynecologic Oncology, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030.

References 

  1. Green TH. Hemisulfur mustard in the palliation of patients with metastatic ovarian carcinoma. Obstet Gynecol. 1959;13:383–393
  2. Suhrland LG, Weisberger AS. Intracavitary 5-fluorouracil in malignant effusions. Arch Intern Med. 1965;116:431–433
  3. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. JAMA. 1955;159:1704–1707
  4. Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62:1–9
  5. Alberts DS, Young L, Mason N, et al. In vitro evaluation of anticancer drugs against ovarian cancer at concentrations achievable by intraperitoneal administration. Semin Oncol. 1985;12:38–42
  6. Litterst CL, Collins JM, Lowe MC, et al. Local and systemic toxicity resulting from large-volume ip administration of doxorubicin in the rat. Cancer Treat Rep. 1982;66:157–161
  7. Litterst CL, Torres IJ, Arnold S, et al. Absorption of antineoplastic drugs following large-volume ip administration of rats. Cancer Treat Rep. 1982;66:147–155
  8. Los G, Mutsaers PHA, van der Vijgh WJF, et al. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy. Cancer Res. 1989;49:3380–3384
  9. Los G, Verdegaal EM, Mutsaers PH, et al. Penetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy. Cancer Chemother Pharmacol. 1991;28:159–165
  10. Markman M. Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity. Crit Rev Oncol Hematol. 1993;14:15–28
  11. Francis P, Rowinsky E, Schneider J, et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group Pilot Study. J Clin Oncol. 1995;13:2961–2967
  12. Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97:845–851
  13. Markman M. Intraperitoneal drug delivery of antineoplastics. Drugs. 2001;61:1057–1065
  14. Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal taxol: A Gynecologic Oncology Group study. J Clin Oncol. 1992;10:1485–1491
  15. Markman M. Intraperitoneal antineoplastic drug delivery: Rationale and results. Lancet Oncol. 2003;4:277–283
  16. Markman M, George M, Hakes T, et al. Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer. J Clin Oncol. 1990;8:146–150
  17. Markman M, Reichman B, Hakes T, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin. J Clin Oncol. 1991;9:1801–1805
  18. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950–1955
  19. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43
  20. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001–1007
  21. Barakat RR, Almadrones L, Venkatraman ES, et al. A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment. Gynecol Oncol. 1998;69:17–22
  22. Howell SB, Zimm S, Markman M, et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol. 1987;5:1607–1612
  23. Markman M, Reichman B, Hakes T, et al. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. J Clin Oncol. 1992;10:1479–1484
  24. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6
  25. Shapiro F, Schneider J, Markman M, et al. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: A pilot trial with ten-year follow-up. Gynecol Oncol. 1997;67:39–45
  26. Markman M, Brady MF, Spirtos NM, et al. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: A Gynecologic Oncology Group Study. J Clin Oncol. 1998;16:2620–2624

 This activity is supported by an unrestricted educational grant from MedImmune Oncology, Inc, a subsidiary of MedImmune, Inc.

PII: S0093-7754(06)00424-6

doi: 10.1053/j.seminoncol.2006.11.002

Seminars in Oncology
Volume 33 , Pages 3-7 , December 2006

Article Tools